Completed PHASE3 INTERVENTIONAL 2-arm NCT01087723

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (EUROMAX)

Multi-centre, Multi-national, Prospective, Randomised, Open-label, Comparison of Bivalirudin to Other Guideline Based Current Therapies (Excluding Bivalirudin)

Sponsor: The Medicines Company

Conditions Acute Coronary Syndrome

Interventions Bivalirudin Heparin

Updated 7 times since 2017 Last updated: Jan 13, 2016 Started: Mar 31, 2010 Primary completion: Aug 31, 2013 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Coronary Syndrome, this trial is completed. The trial is conducted by The Medicines Company and has accumulated 7 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Mar 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Mar 2026 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Amersfoort, Netherlands , Aubervilliers, France , Bad Nauheim, Germany , Berlin, Germany , Bobigny, France , Bologna, Italy , Bordeaux, France , Bourg-en-Bresse, France , Bourges, France and 85 more locations